AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35263421
Drug: Levonorgestrel Implant
RxNorm normalized name: levonorgestrel IMPLANT KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel Implant (LNG-implant)
Trial: 34111874
Drug: Diagnosis-specific cognitive
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnosis-specific cognitive behavioral therapy (dCBT)
Trial: 32064971
Drug: Extended-cycle regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-cycle regimen of combined oral contraceptive (ethinylestradiol 30μg and levonorgestrel 150μg)
Trial: 37142540
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 100 U/mL (IGlar‐100)
Trial: 35441666
Drug: Befriending therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Befriending therapy
Trial: 37415001
Drug: Midazolam (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (7.5 mg orally)
Trial: 32652528
Drug: Secukinumab 300
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 300 mg every 2 weeks (q2w)
Trial: 32652528
Drug: Secukinumab 300
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 300 mg every 4 weeks (q4w)
Trial: 32184313
Drug: Oral melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral melatonin (Circadin) 2 mg at night for 6 weeks
Trial: 33118052
Drug: Ayahuasca (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayahuasca (single dose)
Trial: 32901672
Drug: Oral aprepitant
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral aprepitant (80 mg), intravenous dexamethasone (8 mg), and palonosetron (0.075 mg)
Trial: 32901672
Drug: Oral placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo, intravenous dexamethasone (4 mg), and palonosetron (0.075 mg)
Trial: 35025993
Drug: Olezarsen 10
RxNorm normalized name: olezarsen 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olezarsen 10 mg every 4 weeks
Trial: 35025993
Drug: Olezarsen 15
RxNorm normalized name: Olezarsen
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olezarsen 15 mg every 2 weeks
Trial: 35025993
Drug: Olezarsen 10
RxNorm normalized name: olezarsen 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olezarsen 10 mg every week
Trial: 35025993
Drug: Olezarsen 50
RxNorm normalized name: Olezarsen
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olezarsen 50 mg every 4 weeks
Trial: 34371824
Drug: Crocodile blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crocodile blood supplementation (CB) - 1 g day−1 for 18 days
Trial: 34180141
Drug: Combined Metabolic
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Metabolic Activators (CMAs) including l-serine, N-acetyl-l-cysteine, nicotinamide riboside, and l-carnitine tartrate
Trial: 33096365
Drug: Take-home naloxone
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Take-home naloxone (THN) kits, including two doses of naloxone
Trial: 35811182
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus home exercise program (ST+HEP)
Trial: 32195861
Drug: Antibiotic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic group (cephalexin 500 mg every 6 hours for 7 days)
Trial: 32195861
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (identical capsules)
Trial: 34309926
Drug: Machine Learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine Learning (ML) algorithm for automatic classification of fetal occiput position using transperineal ultrasound (TPU) images.
Trial: 34689142
Drug: CO2 laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2 laser + AmF/NaF/SnCl2 solution
Trial: 34689142
Drug: AmF/NaF/SnCl2 solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmF/NaF/SnCl2 solution
Trial: 34493253
Drug: Imagery Rescripting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imagery Rescripting (ImRs) therapy
Trial: 34493253
Drug: 3-month SUD
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-month SUD treatment only
Trial: 34493253
Drug: Simultaneous SUD/PTSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous SUD/PTSD treatment
Trial: 34493253
Drug: Sequential SUD/PTSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential SUD/PTSD treatment
Trial: 32553435
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shock-wave therapy (rESWT)
Trial: 32553435
Drug: Ultrasound-guided low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ultrasound-guided low-dose intra-articular steroid injection (20 mg of triamcinolone acetonide)
Trial: 34543477
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg every 3 weeks (35 cycles)
Trial: 32609980
Drug: Amoxicillin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (500 mg every 12 hours for 4 to <10 kg, 1000 mg every 12 hours for 10 to <14 kg, 1500 mg every 12 hours for 14 to <20 kg)
Trial: 33864736
Drug: DS-Cav1 vaccine
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-Cav1 vaccine 50 μg with AlOH
Trial: 33864736
Drug: DS-Cav1 vaccine
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-Cav1 vaccine 150 μg with AlOH
Trial: 33864736
Drug: DS-Cav1 vaccine
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-Cav1 vaccine 500 μg with AlOH
Trial: 33864736
Drug: DS-Cav1 vaccine
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-Cav1 vaccine (all doses)
Trial: 34352922
Drug: Foley with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foley with concurrent prostaglandin (Foley-PGE)
Trial: 34352922
Drug: Foley with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foley with concurrent oxytocin (Foley-oxytocin)
Trial: 32629657
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (nonoperative treatment)
Trial: 33480569
Drug: Intravenous iopamidol
RxNorm normalized name: Iopamidol
DrugBank: Iopamidol (DB08947)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous iopamidol at a dose of 480 mg iodine (I)/kg, sampled at 5 min, 1 hr, 6 hr, 24 hr, and 48 hr postinjection.
Trial: 35640175
Drug: Muramyl peptides
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muramyl peptides (200 micrograms administered intramuscularly daily for 7 days)
Trial: 35938325
Drug: Electroacupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture combined with conventional western medicine therapy
Trial: 35938325
Drug: Conventional western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional western medicine therapy
Trial: 39186921
Drug: Valbenazine 80
RxNorm normalized name: valbenazine 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valbenazine 80 mg
Trial: 39186921
Drug: Valbenazine 40
RxNorm normalized name: valbenazine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valbenazine 40 mg
Trial: 32403906
Drug: Acidif plus®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acidif plus® (two tablets per day for 7 days)
Trial: 35040415
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) 400 mg OD or 200 mg BID
Trial: 32539079
Drug: Hookworm treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hookworm treatment (25 Necator americanus larvae transcutaneously)
Trial: 33660875
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg daily for 4 weeks
Trial: 32534626
Drug: Anti-SARS-CoV-2 IgG
RxNorm normalized name: Anti-SARS-CoV-2 IgG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-SARS-CoV-2 IgG antibodies testing
Trial: 34076308
Drug: Calcitriol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol (1 μg for 1 week before surgery)
Trial: 35113137
Drug: Intravitreal pegcetacoplan
RxNorm normalized name: Pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravitreal pegcetacoplan monthly (15 mg)
Trial: 35113137
Drug: Intravitreal pegcetacoplan
RxNorm normalized name: Pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravitreal pegcetacoplan every other month (15 mg)
Trial: 33498220
Drug: High NO3‐,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High NO3‐, low NO2‐ (HL; 572 mg NO3‐, 32 mg NO2‐)
Trial: 33498220
Drug: Medium NO3‐,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium NO3‐, medium NO2‐ (MM; 280 mg NO3‐, 237 mg NO2‐)
Trial: 33498220
Drug: Low NO3‐,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low NO3‐, medium NO2‐ (LM; 43 mg NO3‐, 262 mg NO2‐)
Trial: 33498220
Drug: Placebo (PL;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL; low NO3‐, low NO2‐: 8 mg NO3‐, 5.8 mg NO2‐)
Trial: 32946355
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (NFT)
Trial: 33734043
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no anti-inflammatory therapy)
Trial: 34538546
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of 8-mg intravenous dexamethasone (1D-group)
Trial: 34538546
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of 8-mg intravenous dexamethasone (2D-group)
Trial: 34648568
Drug: Immersive Virtual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immersive Virtual Reality (IVR) intervention for three sessions: 4 hours before chemotherapy, 5 minutes before and during the first course chemotherapy, and 5 minutes before and during the second course chemotherapy.
Trial: 32536538
Drug: Liposomal lidocaine-prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal lidocaine-prilocaine formulation
Trial: 32536538
Drug: Non-liposomal lidocaine-prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-liposomal lidocaine-prilocaine formulation
Trial: 35698000
Drug: Secukinumab low
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Secukinumab low dose (LD) 75/75/150 mg
Trial: 35698000
Drug: Secukinumab high
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Secukinumab high dose (HD) 75/150/300 mg
Trial: 35129211
Drug: Binocular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Binocular treatment
Trial: 33713826
Drug: Post-discharge low-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-discharge low-molecular-weight heparin (LMWH) injections once-daily for 30 days
Trial: 33713826
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections once-daily for 30 days
Trial: 34787919
Drug: TMFI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMFI treatment (Tixel®, Novoxel®, Israel)
Trial: 34787919
Drug: NAFL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAFL treatment (non‐ablative fractional 1565 nm laser, ResurFX®, Lumenis, Israel)
Trial: 34787919
Drug: Both TMFI
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both TMFI and NAFL treatments
Trial: 35413873
Drug: Silver diamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver diamine fluoride (SDF) treatment
Trial: 35413873
Drug: Standard package
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard package of glass ionomer sealants and atraumatic restorative treatment (ART)
Trial: 35413873
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of SDF and standard treatment
Trial: 32398581
Drug: Control (sham
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (sham leg wrapping and saline infusion)
Trial: 34553463
Drug: Ashwagandha root
RxNorm normalized name: ashwagandha root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ashwagandha root extract (300 mg twice daily)
Trial: 32051393
Drug: CCR3 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CCR3 inhibitor SB328437
Trial: 35310186
Drug: Crizotinib combined
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Crizotinib combined with chemotherapy (EG)
Trial: 35310186
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (CG)
Trial: 33793050
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg vitamin C from drink
Trial: 33793050
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg vitamin C from kiwifruit
Trial: 32609534
Drug: Goreisan (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goreisan (2.5 g orally on the night before surgery and on the morning of surgery)
Trial: 33145897
Drug: RCTs evaluating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCTs evaluating outcomes relevant to children's oral health; specific interventions not available.
Trial: 34801112
Drug: PfSPZ Vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ Vaccine (1.8 x 10^6 PfSPZ)
Trial: 34510395
Drug: Oral supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplementation with sucrosomial magnesium associated with therapeutic exercise
Trial: 33512679
Drug: Therapeutic cancer
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic cancer vaccines, specific details not available.
Trial: 33512679
Drug: Combination partners
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination partners (e.g., checkpoint inhibitors), specific details not available.
Trial: 33512679
Drug: Randomized, phase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized, phase 3 studies of therapeutic cancer vaccines, specific details not available.
Trial: 34652627
Drug: 10% (20AA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% (20AA) compound AA injection
Trial: 34652627
Drug: 8.5% (18AA‐II)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8.5% (18AA‐II) compound AA injection
Trial: 34652627
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition support therapy with iso‐nitrogen and iso‐calorie
Trial: 35341360
Drug: VR-based mirror
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VR-based mirror therapy (VR-MT)
Trial: 33745372
Drug: Conventional occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional occupational therapy (COT)
Trial: 33050728
Drug: Automated insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Automated insulin delivery
Trial: 34346295
Drug: Chitosan at
RxNorm normalized name: Chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan at 0 mg/kg concentrate
Trial: 34346295
Drug: Chitosan at
RxNorm normalized name: Chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan at 400 mg/kg concentrate
Trial: 34346295
Drug: Chitosan at
RxNorm normalized name: Chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan at 800 mg/kg concentrate
Trial: 34346295
Drug: Chitosan at
RxNorm normalized name: Chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan at 1200 mg/kg concentrate
Trial: 34346295
Drug: Chitosan at
RxNorm normalized name: Chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan at 1600 mg/kg concentrate
Trial: 616852791
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: tube voltage 100 kV; contrast agent iohexol (350 mg I/ml), reconstructed by filtered back projection
Trial: 616852791
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: tube voltage 80 kV; contrast agent iodixanol (270 mg I/ml), reconstructed by algebraic reconstruction technique
Trial: 32243576
Drug: O-R brush
RxNorm normalized name: OSTOMY SET,STERILE O.R.GUARDIAN H#4673
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O-R brush (Oral-B iO)
Trial: 35034345
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 25000 I.U. oral solution under fed conditions
Trial: 33522946
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 500,000 IU cholecalciferol (5 capsules of 100,000 IU)
Trial: 616836595
Drug: Anhydrous caffeine
RxNorm normalized name: Anhydrous caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anhydrous caffeine (5 mg/kg)
Trial: 35799756
Drug: Hydroxychloroquine Sulfate
RxNorm normalized name: Hydroxychloroquine Sulfate
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine Sulfate (200 mg orally 8 hourlies thrice a day for 5 days)
Trial: 35799756
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Hydroxychloroquine, Oseltamivir, and Azithromycin
Trial: 32151803
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) at 10 mg/kg/day up-titrated to 20-30 mg/kg/day for 12 weeks
Trial: 32151803
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) 30 mg/kg/day
Trial: 33756376
Drug: Integrated Exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated Exposure Therapy (I-PE)
Trial: 33756376
Drug: Integrated Coping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated Coping Skills Therapy (I-CS)
Trial: 34896126
Drug: Topical Chlorhexidine
RxNorm normalized name: chlorhexidine Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Chlorhexidine 0.2%
Trial: 34896126
Drug: Topical Natamycin
RxNorm normalized name: Natamycin
DrugBank: Natamycin (DB00826)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical Natamycin 5%
Trial: 32782077
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of EMLA cream and massage
Trial: 33706032
Drug: TB treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TB treatment support tools (TB‐TSTs)
Trial: 34222086
Drug: Methylethylpiridinol addition
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylethylpiridinol addition to therapy
Trial: 33626929
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy and local therapy (radiation, surgery, thermal ablation)
Trial: 35251416
Drug: Dexamethasone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (1 ml infiltration injection)
Trial: 35251416
Drug: Methylprednisolone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (1 ml infiltration injection)
Trial: 34281377
Drug: Control arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm (intravenous alteplase)
Trial: 34907038
Drug: Sociological variety
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sociological variety indicators (e.g., crowding, movement, livelihoods, recreational activity)
Trial: 34907038
Drug: Socially open
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Socially open communities with poor ventilation (e.g., watching video shows)
Trial: 34907038
Drug: Adjustments to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjustments to socio-spatial aspects (e.g., increasing ventilation on transport)
Trial: 33338662
Drug: Nebulized sodium
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized sodium nitrite (15 mg twice daily)
Trial: 34182998
Drug: BGF 320/14.4/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGF 320/14.4/10 μg